Truist Securities Initiates Coverage On Caribou Biosciences with Buy Rating, Announces Price Target of $23
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has initiated coverage on Caribou Biosciences (NASDAQ:CRBU) with a Buy rating and a price target of $23.
July 11, 2023 | 6:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Caribou Biosciences has been given a Buy rating by Truist Securities with a price target of $23.
The Buy rating and price target set by Truist Securities indicates a positive outlook for Caribou Biosciences. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100